25 results on '"D'Souza, Deepak Cyril"'
Search Results
2. The Psychosis-like Effects of Δ9-Tetrahydrocannabinol Are Associated With Increased Cortical Noise in Healthy Humans
- Author
-
Cortes-Briones, Jose A, Cahill, John D, Skosnik, Patrick D, Mathalon, Daniel H, Williams, Ashley, Sewell, R Andrew, Roach, Brian J, Ford, Judith M, Ranganathan, Mohini, and D’Souza, Deepak Cyril
- Subjects
Biological Psychology ,Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Psychology ,Drug Abuse (NIDA only) ,Neurosciences ,Mental Health ,Clinical Trials and Supportive Activities ,Substance Misuse ,Serious Mental Illness ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Mental health ,Adolescent ,Adult ,Cerebral Cortex ,Dose-Response Relationship ,Drug ,Double-Blind Method ,Dronabinol ,Electroencephalography ,Female ,Hallucinogens ,Healthy Volunteers ,Humans ,Male ,Noise ,Psychiatric Status Rating Scales ,Psychotic Disorders ,Young Adult ,Cannabinoids ,Electroencephalogram ,Neural noise ,Nonlinear analysis ,Psychosis ,Tetrahydrocannabinol ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Psychiatry ,Biological sciences ,Biomedical and clinical sciences - Abstract
BackgroundDrugs that induce psychosis may do so by increasing the level of task-irrelevant random neural activity or neural noise. Increased levels of neural noise have been demonstrated in psychotic disorders. We tested the hypothesis that neural noise could also be involved in the psychotomimetic effects of delta-9-tetrahydrocannabinol (Δ(9)-THC), the principal active constituent of cannabis.MethodsNeural noise was indexed by measuring the level of randomness in the electroencephalogram during the prestimulus baseline period of an oddball task using Lempel-Ziv complexity, a nonlinear measure of signal randomness. The acute, dose-related effects of Δ(9)-THC on Lempel-Ziv complexity and signal power were studied in humans (n = 24) who completed 3 test days during which they received intravenous Δ(9)-THC (placebo, .015 and .03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design.ResultsΔ(9)-THC increased neural noise in a dose-related manner. Furthermore, there was a strong positive relationship between neural noise and the psychosis-like positive and disorganization symptoms induced by Δ(9)-THC, which was independent of total signal power. Instead, there was no relationship between noise and negative-like symptoms. In addition, Δ(9)-THC reduced total signal power during both active drug conditions compared with placebo, but no relationship was detected between signal power and psychosis-like symptoms.ConclusionsAt doses that produced psychosis-like effects, Δ(9)-THC increased neural noise in humans in a dose-dependent manner. Furthermore, increases in neural noise were related with increases in Δ(9)-THC-induced psychosis-like symptoms but not negative-like symptoms. These findings suggest that increases in neural noise may contribute to the psychotomimetic effects of Δ(9)-THC.
- Published
- 2015
3. Revisiting the Consequences of Adolescent Cannabinoid Exposure Through the Lens of the Endocannabinoid System
- Author
-
Ganesh, Suhas, Vidya, K.L., Rashid, Ali Abbas, Singh, Jatinder, and D’Souza, Deepak Cyril
- Published
- 2018
- Full Text
- View/download PDF
4. The early identification of psychosis: can lessons be learnt from cardiac stress testing?
- Author
-
Gupta, Swapnil, Ranganathan, Mohini, and D’Souza, Deepak Cyril
- Published
- 2016
- Full Text
- View/download PDF
5. Impact of Cannabis Use on the Development of Psychotic Disorders
- Author
-
Wilkinson, Samuel T., Radhakrishnan, Rajiv, and D’Souza, Deepak Cyril
- Published
- 2014
- Full Text
- View/download PDF
6. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis.
- Author
-
D'Souza, Deepak Cyril, DiForti, Marta, Ganesh, Suhas, George, Tony P., Hall, Wayne, Hjorthøj, Carsten, Howes, Oliver, Keshavan, Matcheri, Murray, Robin M., Nguyen, Timothy B, Pearlson, Godfrey D., Ranganathan, Mohini, Selloni, Alex, Solowij, Nadia, and Spinazzola, Edoardo
- Subjects
- *
TASK forces , *CANNABINOIDS , *PSYCHOSES , *LITERATURE reviews - Abstract
The liberalisation of cannabis laws, the increasing availability and potency of cannabis has renewed concern about the risk of psychosis with cannabis. The objective of the WFSBP task force was to review the literature about this relationship. Converging lines of evidence suggest that exposure to cannabis increases the risk for psychoses ranging from transient psychotic states to chronic recurrent psychosis. The greater the dose, and the earlier the age of exposure, the greater the risk. For some psychosis outcomes, the evidence supports some of the criteria of causality. However, alternate explanations including reverse causality and confounders cannot be conclusively excluded. Furthermore, cannabis is neither necessary nor sufficient to cause psychosis. More likely it is one of the multiple causal components. In those with established psychosis, cannabis has a negative impact on the course and expression of the illness. Emerging evidence also suggests alterations in the endocannabinoid system in psychotic disorders. Given that exposure to cannabis and cannabinoids is modifiable, delaying or eliminating exposure to cannabis or cannabinoids, could potentially impact the rates of psychosis related to cannabis, especially in those who are at high risk for developing the disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Cannabis and psychosis/schizophrenia: human studies
- Author
-
D’Souza, Deepak Cyril, Sewell, Richard Andrew, and Ranganathan, Mohini
- Published
- 2009
- Full Text
- View/download PDF
8. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans
- Author
-
D’Souza, Deepak Cyril, Pittman, Brian, Perry, Edward, and Simen, Arthur
- Published
- 2009
- Full Text
- View/download PDF
9. Greater vulnerability to the amnestic effects of ketamine in males
- Author
-
Morgan, Celia J. A., Perry, Edward B., Cho, Hyung-Sang, Krystal, John H., and D’Souza, Deepak Cyril
- Published
- 2006
- Full Text
- View/download PDF
10. Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review.
- Author
-
Lees, Rachel, Hines, Lindsey A., D'Souza, Deepak Cyril, Stothart, George, Di Forti, Marta, Hoch, Eva, and Freeman, Tom P.
- Subjects
SUBSTANCE abuse treatment ,CANNABIS (Genus) ,SUBSTANCE abuse ,MOTIVATIONAL interviewing ,PSYCHOSES ,MENTAL health ,COMORBIDITY ,PSYCHOTHERAPY ,COGNITIVE therapy ,DISEASE complications - Abstract
Cannabis is the most widely used illicit drug worldwide, and it is estimated that up to 30% of people who use cannabis will develop a cannabis use disorder (CUD). Demand for treatment of CUD is increasing in almost every region of the world and cannabis use is highly comorbid with mental disorders, where sustained use can reduce treatment compliance and increase risk of relapse. In this narrative review, we outline evidence for psychosocial and pharmacological treatment strategies for CUD, both alone and when comorbid with psychosis, anxiety or depression. Psychosocial treatments such as cognitive behavioural therapy, motivational enhancement therapy and contingency management are currently the most effective strategy for treating CUD but are of limited benefit when comorbid with psychosis. Pharmacological treatments targeting the endocannabinoid system have the potential to reduce cannabis withdrawal and cannabis use in CUD. Mental health comorbidities including anxiety, depression and psychosis hinder effective treatment and should be addressed in treatment provision and clinical decision making to reduce the global burden of CUDs. Antipsychotic medication may decrease cannabis use and cannabis craving as well as psychotic symptoms in patients with CUD and psychosis. Targeted treatments for anxiety and depression when comorbid with CUD are feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Cannabis and Psychosis: Recent Epidemiological Findings Continuing the "Causality Debate".
- Author
-
Ganesh, Suhas and D'Souza, Deepak Cyril
- Subjects
- *
MARIJUANA , *PSYCHOSES , *SCHIZOPHRENIA - Abstract
The authors reflect on the epidemiological studies on the connection between cannabis use and psychosis. Also cited are a study showing an increased prevalence of self-reported psychotic disorders among adolescents and young adults in the U.S., the relationship between proxy measures of dose and self-reported psychosis, and the genome-wide association studies (GWAS) of schizophrenia and lifetime cannabis use.
- Published
- 2022
- Full Text
- View/download PDF
12. Characterizing psychosis-relevant phenomena and cognitive function in a unique population with isolated, chronic and very heavy cannabis exposure.
- Author
-
D'Souza, Deepak Cyril, Ganesh, Suhas, Cortes-Briones, Jose, Campbell, Michael H., and Emmanuel, Maisha K.
- Subjects
- *
COGNITION disorder risk factors , *ATTENTION , *CANNABIS (Genus) , *COGNITIVE testing , *CULTURE , *HEALTH attitudes , *MEMORY , *PSYCHOLOGY of movement , *PSYCHOSES , *QUESTIONNAIRES , *RISK assessment , *SCHIZOTYPAL personality disorder , *SUBSTANCE abuse , *LIFESTYLES , *CASE-control method , *DESCRIPTIVE statistics , *DISEASE complications - Abstract
Background: The literature on psychosis-relevant outcomes in cannabis users does not adequately address the confounding effects of other substance use/misuse and psychiatric disorders. Methods: We studied a unique population for whom cannabis use is central and necessary to their way of life. They are forbidden from using other substances, including tobacco and alcohol. Their use of cannabis is heavy, chronic, and begins early. The cases were compared with matched controls who did not use cannabis, alcohol, or drugs. The controls were from the same location and shared similar beliefs and lifestyle, except for cannabis use. Attenuated psychosis-relevant phenomena were assessed with the Schizotypal Personality Questionnaire (SPQ) and cognitive functioning with a culture-neutral computerized cognitive battery. Results: Fifteen cases and 12 matched controls were studied. The cases averaged >30 000 lifetime cannabis exposures. Relative to controls, the cases had significantly higher mean (s.d.) SPQ scores 24 (14.32) v. 13 (8.92), p = 0.031; and poorer cognitive performance, reflected by a lower mean (s.d.) composite cognitive score −0.23 (0.32) v. +0.28 (0.52), p = 0.03. Moderate to large effect sizes were noted for differences in tests of attention, psychomotor speed, working memory, cognitive flexibility, visuo-spatial processing, and verbal memory. A subsample of cases had higher SPQ scores and worse cognitive performance than their siblings not using cannabis. Conclusion: Heavy, chronic, and early cannabis use that is not confounded by other drug use is associated with psychosis-relevant phenomena and cognitive deficits. The findings are relevant to the evolving attitudes and laws about cannabis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.
- Author
-
Ganesh, Suhas, Cortes-Briones, Jose, Ranganathan, Mohini, Radhakrishnan, Rajiv, Skosnik, Patrick D, and D'Souza, Deepak Cyril
- Subjects
TETRAHYDROCANNABINOL ,HUMAN experimentation ,INTRAVENOUS therapy ,CANNABINOIDS ,MARIJUANA ,MARIJUANA growing - Abstract
Introduction There is increasing interest in the relationship between cannabinoids and psychosis. While individual human laboratory studies have been critical in demonstrating that cannabinoids (e.g. delta-9-tetrahydrocannabinol [THC]) can induce acute transient psychosis-like effects in healthy human volunteers, combining data from multiple studies offers a fine-grained view of these effects. Methods THC-induced psychosis-relevant effects were examined using a data repository of 10 double-blind, randomized, placebo-controlled, crossover studies with 400 i.v. THC infusions in healthy human volunteers. The Positive and Negative Syndrome scale was used to measure psychotomimetic effects. The profile of symptoms, frequency of a response, its relationship to THC dose and substance use, latent structure in Positive and Negative Syndrome scale response, and the relationships between psychotomimetic and perceptual alteration symptoms were evaluated. Results Clinically meaningful increases in positive symptoms were noted in 44.75% infusions; conceptual disorganization, hallucinations, blunted affect, somatic concern, motor retardation, and poor attention were the items most frequently altered by THC. The increase in Positive and Negative Syndrome scale positive symptoms was positively associated with THC dose (beta = 11.13, SE = 4.94, Wald χ
2 = 19.88, P < . 001) and negatively associated with frequent cannabis use (beta = −0.575, SE = 0.14, Wald χ2 =s = 0.514, P < . 001). Conclusion Intravenous administration of THC consistently induces psychotomimetic effects that include symptoms across Positive and Negative Syndrome scale domains. Moreover, healthy individuals who frequently use cannabis have a blunted psychotomimetic response. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Gone to pot -- a review of the association between cannabis and psychosis.
- Author
-
Radhakrishnan, Rajiv, Wilkinson, Samuel T., D'Souza, Deepak Cyril, Hillemacher, Thomas, and Temple, Elizabeth Clare
- Subjects
CANNABIS (Genus) ,PSYCHOSES risk factors ,ETIOLOGY of diseases ,PSYCHOPHYSIOLOGY ,SCHIZOPHRENIA - Abstract
Cannabis is the most commonly used illicit drug worldwide, with ∼5 million daily users worldwide. Emerging evidence supports a number of associations between cannabis and psychosis/psychotic disorders, including schizophrenia. These associations-based on case-studies, surveys, epidemiological studies, and experimental studies indicate that cannabinoids can produce acute, transient effects; acute, persistent effects; and delayed, persistent effects that recapitulate the psychopathology and psychophysiology seen in schizophrenia. Acute exposure to both cannabis and synthetic cannabinoids (Spice/K2) can produce a full range of transient psychotomimetic symptoms, cognitive deficits, and psychophysiological abnormalities that bear a striking resemblance to symptoms of schizophrenia. In individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. Several factors appear to moderate these associations, including family history, genetic factors, history of childhood abuse, and the age at onset of cannabis use. Exposure to cannabinoids in adolescence confers a higher risk for psychosis outcomes in later life and the risk is dose-related. Individuals with polymorphisms of COMT and AKT1 genes may be at increased risk for psychotic disorders in association with cannabinoids, as are individuals with a family history of psychotic disorders or a history of childhood trauma. The relationship between cannabis and schizophrenia fulfills many but not all of the standard criteria for causality, including temporality, biological gradient, biological plausibility, experimental evidence, consistency, and coherence. At the present time, the evidence indicates that cannabis may be a component cause in the emergence of psychosis, and this warrants serious consideration from the point of view of public health policy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
15. Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia
- Author
-
D'Souza, Deepak Cyril, Ahn, Kyungheup, Bhakta, Savita, Elander, Jacqueline, Singh, Nagendra, Nadim, Haleh, Jatlow, Peter, Suckow, Raymond F., Pittman, Brian, and Ranganathan, Mohini
- Subjects
- *
NICOTINE , *KETAMINE , *COGNITION disorders treatment , *SCHIZOPHRENIA , *METHYL aspartate receptors , *NICOTINIC acetylcholine receptors , *PLACEBOS , *RANDOMIZED controlled trials - Abstract
Background: The uncompetitive N-methyl-D-aspartate receptor (NMDAR) antagonist, ketamine, induces a range of symptoms resembling those seen in schizophrenia. Enhancement of nicotinic acetylcholine receptor (nAChR) function may have potential as a treatment for the cognitive deficits and negative symptoms of schizophrenia. Accordingly, we examined the modulatory effects of brain nAChR systems on NMDAR antagonist-induced effects. Methods: The interactive effects of ketamine and nicotine were evaluated in 37 healthy subjects in a randomized, placebo-controlled, double-blind, crossover counterbalanced, 2 (intravenous ketamine or placebo) × 2 (intravenous nicotine or placebo) design. Verbal and visual memory, sustained attention, working memory, response inhibition, emotion recognition, executive function, reaction time, motor function, and speed of processing were assessed once per test day, while negative and positive symptoms, perceptual alterations, and a number of feeling states were measured several times before and after administration of drugs. Results: Ketamine induced cognitive deficits and negative and positive symptoms. Nicotine worsened immediate recall, auditory working memory, response inhibition, and executive function and serial processing. Nicotine decreased (improved) reaction time on the sustained attention and choice reaction time tasks. Nicotine did not reduce ketamine-induced cognitive deficits or negative and positive symptoms. Conclusions: At blood levels comparable with tobacco smoking, nicotine infusion does not appear to alleviate the ketamine-induced transient cognitive and behavioral effects in healthy subjects that resemble those seen in schizophrenia. The lack of an effect of nicotine on a spectrum of ketamine effects suggests that the consequences of NMDAR antagonism are not likely under the direct influence of nAChR. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
16. Probing GABA Receptor Function in Schizophrenia with Iomazenil.
- Author
-
Ahn, Kyungheup, Gil, Roberto, Seibyl, John, Sewell, Richard Andrew, and D'Souza, Deepak Cyril
- Subjects
GABA receptors ,SCHIZOPHRENIA risk factors ,PEOPLE with schizophrenia ,BENZODIAZEPINE antagonists ,PSYCHOSES ,RANDOMIZED controlled trials ,PSYCHOLOGY - Abstract
Several lines of evidence from post-mortem, brain imaging, and genetic studies in schizophrenia patients suggest that Gamma-amino butyric acid (GABA) deficits may contribute to the pathophysiology of schizophrenia. Pharmacological induction of a transient GABA-deficit state has been shown to enhance vulnerability of healthy subjects to the psychotomimetic effects of various drugs. Exacerbating or creating a GABA deficit was hypothesized to induce or unmask psychosis in schizophrenia patients, but not in healthy controls. To test this hypothesis, a transient GABA deficit was pharmacologically induced in schizophrenia patients and healthy controls using iomazenil, an antagonist and partial inverse agonist of the benzodiazepine receptor. In a double-blind, randomized, placebo-controlled study, clinically stable chronic schizophrenia patients (n=13) received iomazenil (3.7 μg administered intravenously over 10 min). Psychosis was measured using the Brief Psychiatric Rating Scale and perceptual alterations were measured using the Clinician Administered Dissociative Symptoms Scale before and after iomazenil administration. These data were compared with the effects of iomazenil in healthy subjects (n=20). Iomazenil produced increases in psychotic symptoms and perceptual alterations in schizophrenia patients, but not in healthy controls. The greater vulnerability of schizophrenia patients to the effects of iomazenil relative to controls provides further support for the GABA-deficit hypothesis of schizophrenia. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Cannabis and psychosis/schizophrenia: human studies.
- Author
-
D'Souza, Deepak Cyril, Sewell, Richard Andrew, and Ranganathan, Mohini
- Subjects
- *
CANNABIS (Genus) , *PSYCHOSES , *SCHIZOPHRENIA , *DOPAMINE , *NEURAL transmission , *PEOPLE with schizophrenia - Abstract
The association between cannabis use and psychosis has long been recognized. Recent advances in knowledge about cannabinoid receptor function have renewed interest in this association. Converging lines of evidence suggest that cannabinoids can produce a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. Also clear is that in individuals with an established psychotic disorder, cannabinoids can exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness. The mechanisms by which cannabinoids produce transient psychotic symptoms, while unclear may involve dopamine, GABA, and glutamate neurotransmission. However, only a very small proportion of the general population exposed to cannabinoids develop a psychotic illness. It is likely that cannabis exposure is a “component cause” that interacts with other factors to “cause” schizophrenia or a psychotic disorder, but is neither necessary nor sufficient to do so alone. Nevertheless, in the absence of known causes of schizophrenia, the role of component causes remains important and warrants further study. Dose, duration of exposure, and the age of first exposure to cannabinoids may be important factors, and genetic factors that interact with cannabinoid exposure to moderate or amplify the risk of a psychotic disorder are beginning to be elucidated. The mechanisms by which exposure to cannabinoids increase the risk for developing a psychotic disorder are unknown. However, novel hypotheses including the role of cannabinoids on neurodevelopmental processes relevant to psychotic disorders are being studied. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
18. Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism.
- Author
-
Krystal, John H., Madonick, Steven, Perry, Edward, Gueorguieva, Ralitza, Brush, Laura, Wray, Yola, Belger, Aysenil, and D'Souza, Deepak Cyril
- Subjects
NALTREXONE ,NARCOTIC antagonists ,KETAMINE ,ALCOHOLISM ,SUBSTANCE abuse ,DRUG therapy - Abstract
The interplay of opiate and NMDA glutamate receptors may contribute to psychosis, cognitive function, alcoholism, and substance dependence. Ketamine and ethanol block the NMDA glutamate receptor. The purpose of this randomized double-blind, placebo-controlled human laboratory study was to evaluate whether the interactive effects of drugs acting at opiate and NMDA glutamate receptors might partially explain the efficacy of naltrexone for the treatment of alcoholism, that is, whether naltrexone 25 mg pretreatment would modulate ketamine effects in healthy human subjects. Two groups of healthy subjects were studied. An initial group (n=31) received a perception-altering subanesthetic dose of ketamine (bolus of 0.23 mg/kg over 1 min followed by a 60-min infusion of 0.58 mg/kg or saline bolus and infusion). A second group (n=24) completed the same testing procedures, but received a subperceptual ketamine dose (bolus 0.081 mg/kg over 10 min followed by an infusion of 0.4 mg/kg/h). Ketamine produced positive symptoms, negative symptoms, emotional discomfort, and cognitive effects as measured by the Positive and Negative Syndrome Scale (PANSS) in a dose-related fashion. The lower ketamine dose produced subjective effects similar to two standard ethanol drinks, whereas the higher ketamine dose produced effects similar to five standard drinks. Although naltrexone produced no significant behavioral effects, it significantly magnified the increase in the total PANSS score produced by the lower subperceptual dose of ketamine, but not the higher perception-altering dose of ketamine. These data suggest that the interplay of opiate receptor antagonism and NMDA receptor antagonism may be relevant to the protective effects of naltrexone on alcohol consumption via potentiation of dysphoric effects associated with the NMDA receptor antagonist effects of ethanol. However, these data suggest that at levels of NMDA receptor antagonism associated with heavy drinking, this protective effect of naltrexone on drinking is no longer present.Neuropsychopharmacology (2006) 31, 1793–1800. doi:10.1038/sj.npp.1300994; published online 4 January 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
19. γ-Aminobutyric Acid–Serotonin Interactions in Healthy Men: Implications for Network Models of Psychosis and Dissociation
- Author
-
D’Souza, Deepak Cyril, Gil, Roberto B., Zuzarte, Edward, MacDougall, Lisa M., Donahue, Lia, Ebersole, John S., Boutros, Nashaat N., Cooper, Tom, Seibyl, John, and Krystal, John H.
- Subjects
- *
AMINOBUTYRIC acid , *GABA receptors , *SEROTONINERGIC mechanisms , *BENZODIAZEPINES , *PLACEBOS - Abstract
Background: This study tested the hypothesis that deficits in γ-aminobutyric acid type A (GABAA) receptor function might create a vulnerability to the psychotogenic and perceptual altering effects of serotonergic (5-HT2A/2C) receptor stimulation. The interactive effects of iomazenil, an antagonist and partial inverse agonist of the benzodiazepine site of the GABAA receptor complex, and m-chlorophenylpiperazine (m-CPP), a partial agonist of 5-HT2A/2C receptors, were studied in 23 healthy male subjects. Methods: Subjects underwent 4 days of testing, during which they received intravenous infusions of iomazenil/placebo followed by m-CPP/placebo in a double-blind, randomized crossover design. Behavioral, cognitive, and hormonal data were collected before drug infusions and periodically for 200 min after. Results: Iomazenil and m-CPP interacted in a synergistic manner to produce mild psychotic symptoms and perceptual disturbances without impairing cognition. Iomazenil and m-CPP increased anxiety in an additive fashion. Iomazenil and m-CPP interacted in a synergistic manner to increase serum cortisol. Conclusions: Gamma-aminobutyric acid-ergic deficits might increase the vulnerability to the psychotomimetic and perceptual altering effects of serotonergic agents. These data suggest that interactions between GABAA and 5-HT systems might contribute to the pathophysiology of psychosis and dissociative-like perceptual states. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
20. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis.
- Author
-
D'Souza, Deepak Cyril, Perry, Edward, MacDougall, Lisa, Ammerman, Yola, Cooper, Thomas, Yu-te Wu, Braley, Gabriel, Gueorguieva, Ralitza, and Krystal, John Harrison
- Subjects
- *
CANNABINOIDS , *CANNABIS (Genus) , *TERPENES , *HALLUCINOGENIC drugs , *PSYCHOSES , *NEUROPSYCHOPHARMACOLOGY - Abstract
Recent advances in the understanding of brain cannabinoid receptor function have renewed interest in the association between cannabinoid compounds and psychosis. In a 3-day, double-blind, randomized, and counterbalanced study, the behavioral, cognitive, and endocrine effects of 0, 2.5, and 5 mg intravenous delta-9-tetrahydrocannabinol (Δ-9-THC) were characterized in 22 healthy individuals, who had been exposed to cannabis but had never been diagnosed with a cannabis abuse disorder. Prospective safety data at 1, 3, and 6 months poststudy was also collected. Δ-9-THC (1) produced schizophrenia-like positive and negative symptoms; (2) altered perception; (3) increased anxiety; (4) produced euphoria; (5) disrupted immediate and delayed word recall, sparing recognition recall; (6) impaired performance on tests of distractibility, verbal fluency, and working memory (7) did not impair orientation; (8) increased plasma cortisol. These data indicate that Δ-9-THC produces a broad range of transient symptoms, behaviors, and cognitive deficits in healthy individuals that resemble some aspects of endogenous psychoses. These data warrant further study of whether brain cannabinoid receptor function contributes to the pathophysiology of psychotic disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
21. Going deep into schizophrenia with artificial intelligence.
- Author
-
Cortes-Briones, Jose A., Tapia-Rivas, Nicolas I., D'Souza, Deepak Cyril, and Estevez, Pablo A.
- Subjects
- *
ARTIFICIAL intelligence , *MACHINE learning , *NONLINEAR systems , *DEEP learning , *CAUSAL models , *SCHIZOPHRENIA treatment , *PROBABILITY theory , *ALGORITHMS - Abstract
Despite years of research, the mechanisms governing the onset, relapse, symptomatology, and treatment of schizophrenia (SZ) remain elusive. The lack of appropriate analytic tools to deal with the heterogeneity and complexity of SZ may be one of the reasons behind this situation. Deep learning, a subfield of artificial intelligence (AI) inspired by the nervous system, has recently provided an accessible way of modeling and analyzing complex, high-dimensional, nonlinear systems. The unprecedented accuracy of deep learning algorithms in classification and prediction tasks has revolutionized a wide range of scientific fields and is rapidly permeating SZ research. Deep learning has the potential of becoming a valuable aid for clinicians in the prediction, diagnosis, and treatment of SZ, especially in combination with principles from Bayesian statistics. Furthermore, deep learning could become a powerful tool for uncovering the mechanisms underlying SZ thanks to a growing number of techniques designed for improving model interpretability and causal reasoning. The purpose of this article is to introduce SZ researchers to the field of deep learning and review its latest applications in SZ research. In general, existing studies have yielded impressive results in classification and outcome prediction tasks. However, methodological concerns related to the assessment of model performance in several studies, the widespread use of small training datasets, and the little clinical value of some models suggest that some of these results should be taken with caution. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
- Author
-
Surti, Toral S., Ranganathan, Mohini, Johannesen, Jason K., Gueorguieva, Ralitza, Deaso, Emma, Kenney, Joshua G., Krystal, John H., and D'Souza, Deepak Cyril
- Subjects
- *
COGNITIVE training , *RANDOMIZED controlled trials , *NEUROPLASTICITY , *GLYCINE , *SCHIZOPHRENIA - Abstract
N -methyl- d -aspartate glutamate receptor (NMDAR) hypofunction is implicated in the impaired neuroplasticity and cognitive impairments associated with schizophrenia (CIAS). We hypothesized that enhancing NMDAR function by inhibiting the glycine transporter-1 (GLYT1) would improve neuroplasticity and thereby augment benefits of non-pharmacological cognitive training (CT) strategies. This study examined whether co-administration of a GLYT1 inhibitor and computerized CT would have synergistic effects on CIAS. Stable outpatients with schizophrenia participated in this double-blind, placebo-controlled, within-subject, crossover augmentation study. Participants received placebo or GLYT1 inhibitor (PF-03463275) for two 5-week periods separated by 2 weeks of washout. PF-03463275 doses (40 or 60 mg twice daily) were selected to produce high GLYT1 occupancy. To limit pharmacodynamic variability, only cytochrome P450 2D6 extensive metabolizers were included. Medication adherence was confirmed daily. Participants received 4 weeks of CT in each treatment period. Cognitive performance (MATRICS Consensus Cognitive Battery) and psychotic symptoms (Positive and Negative Syndrome Scale) were assessed in each period. 71 participants were randomized. PF-03463275 in combination with CT was feasible, safe, and well-tolerated at the doses prescribed but did not produce greater improvement in CIAS compared to CT alone. PF-03463275 was not associated with improved CT learning parameters. Participation in CT was associated with improvement in MCCB scores. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Human Laboratory Studies on Cannabinoids and Psychosis.
- Author
-
Sherif, Mohamed, Radhakrishnan, Rajiv, D’Souza, Deepak Cyril, and Ranganathan, Mohini
- Subjects
- *
CANNABINOIDS , *PSYCHOSES , *PSYCHOSOMATIC disorders , *DRUG administration , *HALLUCINOGENIC drugs , *RANDOMIZED controlled trials - Abstract
Some of the most compelling evidence supporting an association between cannabinoid agonists and psychosis comes from controlled laboratory studies in humans. Randomized, double-blind, placebo-controlled, crossover laboratory studies demonstrate that cannabinoid agonists, including phytocannabinoids and synthetic cannabinoids, produce a wide range of positive, negative, and cognitive symptoms and psychophysiologic deficits in healthy human subjects that resemble the phenomenology of schizophrenia. These effects are time locked to drug administration, are dose related, and are transient and rarely necessitate intervention. The magnitude of effects is similar to the effects of ketamine but qualitatively distinct from other psychotomimetic drugs, including ketamine, amphetamine, and salvinorin A. Cannabinoid agonists have also been shown to transiently exacerbate symptoms in individuals with schizophrenia in laboratory studies. Patients with schizophrenia are more vulnerable than healthy control subjects to the acute behavioral and cognitive effects of cannabinoid agonists and experience transient exacerbation of symptoms despite treatment with antipsychotic medications. Furthermore, laboratory studies have failed to demonstrate any “beneficial” effects of cannabinoid agonists in individuals with schizophrenia—challenging the cannabis self-medication hypothesis. Emerging evidence suggests that polymorphisms of several genes related to dopamine metabolism (e.g., COMT , DAT1 , and AKT1 ) may moderate the effects of cannabinoid agonists in laboratory studies. Cannabinoid agonists induce dopamine release, although the magnitude of release does not appear to be commensurate to the magnitude and spectrum of their acute psychotomimetic effects. Interactions between the endocannabinoid, gamma-aminobutyric acid, and glutamate systems and their individual and interactive effects on neural oscillations provide a plausible mechanism underlying the psychotomimetic effects of cannabinoids. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans
- Author
-
Ranganathan, Mohini, Schnakenberg, Ashley, Skosnik, Patrick D., Cohen, Bruce M., Pittman, Brian, Sewell, R. Andrew, and D'Souza, Deepak Cyril
- Subjects
- *
ENDOCRINE system , *PSYCHOPHYSIOLOGY , *OPIOIDS , *SALVINORIN A , *DRUG abuse , *HALLUCINOGENIC drugs - Abstract
Background: Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults. Its primary active ingredient, Salvinorin A (SA)—a highly selective agonist at the κ opiate receptor—is believed to be one of the most potent naturally occurring hallucinogens. However, there is little experimental data on the effects of SA in humans. Methods: In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiological, and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia. Results: SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting electroencephalogram spectral power. The SA administration was associated with a rapid increase of its levels in the blood. SA did not produce euphoria, cognitive deficits, or changes in vital signs. The effects were transient and not dose-related. SA administration was very well-tolerated without acute or delayed adverse effects. Conclusions: SA produced a wide range of transient effects in healthy subjects. The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern. Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism. Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
25. Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorder
- Author
-
Srihari, Vinod H., Lee, Tih-Shih Warren, Rohrbaugh, Robert M., and D'Souza, Deepak Cyril
- Subjects
- *
PSYCHOSES , *PATHOLOGICAL psychology , *PATHOLOGICAL physiology - Abstract
Abstract: We report a case of recurrent psychosis, spanning decades, with full inter-episode recovery and minimal functional impairment. While it is difficult to classify this disorder using DSM IV-TR criteria, Leonhard and others have described a ‘cycloid psychosis’ that correlates well with the phenomenology and course of this case. We believe this may represent a subset within the ICD-10 category of ‘acute and transient psychotic disorders’. While this disorder, of unknown incidence, is not well reported in the U.S., it is worthy of further investigation and clinical attention given its generally favorable prognosis and potentially distinct pathophysiology and treatment. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.